Dice Therapeutics IncNASDAQ DICE Stock Report

DiCE Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 71 full-time employees. The company went IPO on 2021-09-15. The firm leverages its technology platform to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is focused on developing oral therapeutics against targets in immunology. The Company’s platform, which it refers to as DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. Its lead therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The firm is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).